Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Cancer Survival Analysis01:21

Cancer Survival Analysis

345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Cancer Vaccines01:30

Cancer Vaccines

363
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
363

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Association of Quantitative Background Parenchymal Enhancement with Breast Cancer Risk Among Women with BRCA1/2 Pathogenic Variants.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Cancer research communications·2026
Same author

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).

NPJ breast cancer·2026
Same author

Combining multiplexed assays of variant effect for enhanced BRCA2 variant classification.

Nature communications·2026
Same author

Influence of Tumor-Draining Lymph Nodes on Immunotherapy: Lymphadenectomy May Have Its Limits.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma.

Science (New York, N.Y.)·2026
Same journal

Type II JAK2 Inhibitor Gets Off to a Strong Start.

Cancer discovery·2026
Same journal

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
Same journal

Reconsidering Cancer Therapy through the Lens of Biomolecular Condensates.

Cancer discovery·2026
Same journal

The Promise of Machine Learning-Based Population Screening for Hepatocellular Carcinoma.

Cancer discovery·2026
Same journal

Spatially Resolved Proteomic Cartography Illuminates the Earliest Molecular Programs in Pancreatic Cancer Evolution.

Cancer discovery·2026
Same journal

Oral Regimens for AML Make Strides.

Cancer discovery·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K

Advancing Cancer Interception.

Susan M Domchek1,2,3, Robert H Vonderheide2,3

  • 1Basser Center for BRCA1/2, University of Pennsylvania, Philadelphia, Pen-nsylvania.

Cancer Discovery
|April 4, 2024
PubMed
Summary
This summary is machine-generated.

Cancer interception, using advanced technology and genetic testing, aims to eliminate pre-cancerous conditions. New targeted therapies and immuno-interception strategies require distinct clinical approaches distinct from current cancer treatments.

More Related Videos

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication
07:47

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication

Published on: December 15, 2023

684
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

749

Related Experiment Videos

Last Updated: Jun 29, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.3K
Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication
07:47

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication

Published on: December 15, 2023

684
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

749

Area of Science:

  • Oncology
  • Genetics
  • Therapeutics

Background:

  • Technological and therapeutic advancements are accelerating cancer research.
  • Improved methods for identifying individuals at risk for cancer are emerging.
  • Genetic testing offers new avenues for personalized cancer risk assessment.

Purpose of the Study:

  • To introduce the concept and potential of cancer interception.
  • To highlight the role of targeted therapies and immuno-interception.
  • To emphasize the need for novel clinical trial and treatment paradigms.

Main Methods:

  • Review of recent technological and therapeutic advancements in oncology.
  • Analysis of genetic testing and risk stratification methodologies.
  • Conceptualization of "immuno-interception" strategies.

Main Results:

  • Cancer interception is becoming feasible due to technological progress.
  • Targeted therapies and immuno-interception show promise in eliminating premalignant lesions.
  • Current clinical trial and treatment frameworks are insufficient for interception strategies.

Conclusions:

  • Cancer interception represents a paradigm shift in oncology.
  • Novel therapeutic strategies like targeted therapies and immuno-interception are key.
  • Distinct clinical approaches are necessary to realize the potential of cancer interception.